Patents by Inventor Chakkumkal Anish
Chakkumkal Anish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230257433Abstract: Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.Type: ApplicationFiled: February 20, 2023Publication date: August 17, 2023Inventors: Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
-
Patent number: 11591377Abstract: Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.Type: GrantFiled: April 23, 2020Date of Patent: February 28, 2023Assignees: Janssen Pharmaceuticals, Inc., AC Immune SAInventors: Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
-
Patent number: 10864261Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.Type: GrantFiled: December 16, 2016Date of Patent: December 15, 2020Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
-
Patent number: 10688169Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.Type: GrantFiled: March 29, 2016Date of Patent: June 23, 2020Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
-
Patent number: 10596272Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: January 26, 2016Date of Patent: March 24, 2020Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Chakkumkal Anish, Marilda Lisboa, Christopher Martin, Claney Lebev Pereira, Peter H. Seeberger, Naeem Khan
-
Publication number: 20200016257Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.Type: ApplicationFiled: December 16, 2016Publication date: January 16, 2020Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
-
Patent number: 10328141Abstract: The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.Type: GrantFiled: July 7, 2014Date of Patent: June 25, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann
-
Patent number: 10220083Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: September 28, 2015Date of Patent: March 5, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann, Sharavathi Guddehalli Parameswarappa, Heung Sik Hahm, Subramanian Govindan
-
Patent number: 10188718Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: May 15, 2015Date of Patent: January 29, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Andreas Geissner
-
Publication number: 20180296687Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: ApplicationFiled: January 26, 2016Publication date: October 18, 2018Inventors: Chakkumkal ANISH, Marilda LISBOA, Christopher MARTIN, Claney Lebev PEREIRA, Peter H. SEEBERGER, Naeem KHAN
-
Patent number: 10052373Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.Type: GrantFiled: September 18, 2014Date of Patent: August 21, 2018Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Dominea Rathwell, Sharavathi Guddehalli Parameswarappa, Subramanian Govindan, Chakkumkal Anish, Claney Lebev Pereira, Peter H. Seeberger, Felix Bröcker
-
Publication number: 20180078630Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.Type: ApplicationFiled: March 29, 2016Publication date: March 22, 2018Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
-
Publication number: 20170333545Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: ApplicationFiled: May 15, 2015Publication date: November 23, 2017Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Andreas Geissner
-
Patent number: 9815889Abstract: The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: ?-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[?-L-Rhap-(1?3)]-?-D-Glcp-(1?2)-?-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.Type: GrantFiled: December 10, 2015Date of Patent: November 14, 2017Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
-
Publication number: 20170239341Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: ApplicationFiled: September 28, 2015Publication date: August 24, 2017Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann, Sharavathi Guddehalli Parameswarappa, Heung Sik Hahm, Subramanian Govindan
-
Publication number: 20160346374Abstract: The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.Type: ApplicationFiled: July 7, 2014Publication date: December 1, 2016Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann
-
Publication number: 20160279224Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.Type: ApplicationFiled: September 18, 2014Publication date: September 29, 2016Inventors: Dominea RATHWELL, Sharavathi Guddehalli PARAMESWARAPPA, Subramanian GOVINDAN, Chakkumkal ANISH, Claney Lebev PEREIRA, Peter H. SEEBERGER, Felix BRÖCKER
-
Publication number: 20160137724Abstract: The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: ?-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[?-L-Rhap-(1?3)]-?-D-Glcp-(1?2)-?-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.Type: ApplicationFiled: December 10, 2015Publication date: May 19, 2016Inventors: Peter H. SEEBERGER, Christopher E. MARTIN, Felix BROECKER, Chakkumkal ANISH
-
Patent number: 9238669Abstract: The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[a-L-Rhap-(1?3]-a-D-Glcp-(1?2)-a-D-Glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker L for conjugation to a carrier protein or for immobilization on a surface. Further aspects of the invention relate to advantageous methods for synthesizing said synthetic oligosaccharide and oligosaccharide-protein conjugate as well as to uses thereof, in particular as vaccines and diagnostic tools.Type: GrantFiled: July 30, 2012Date of Patent: January 19, 2016Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e. V.Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
-
Publication number: 20140234364Abstract: The present invention relates to the total chemical synthesis of the monosaccharide 35# (R??H), the disaccharide 36# (R??H; R??H), the trisaccharide 37# (R??H; R??H; R???H) and the tetrasaccharide 1# (R??H; R??H; R???H) of the following general formula wherein R represents —Y—NH2Y represents a linker R? is H or R? is H or R?? is H or of the lipopolysaccharide from Neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or the trisaccharide ?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by Neisseria meningitidis.Type: ApplicationFiled: September 24, 2012Publication date: August 21, 2014Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, You Yang, Chakkumkal Anish, Anika Reinhardt